These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

153 related articles for article (PubMed ID: 27459532)

  • 1. Proteomics Suggests a Role for APC-Survivin in Response to Somatostatin Analog Treatment of Neuroendocrine Tumors.
    Fotouhi O; Kjellin H; Larsson C; Hashemi J; Barriuso J; Juhlin CC; Lu M; Höög A; Pastrián LG; Lamarca A; Soto VH; Zedenius J; Mendiola M; Lehtiö J; Kjellman M
    J Clin Endocrinol Metab; 2016 Oct; 101(10):3616-3627. PubMed ID: 27459532
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Lanreotide for the treatment of gastroenteropancreatic neuroendocrine tumors.
    Saif MW
    Expert Opin Pharmacother; 2016; 17(3):443-56. PubMed ID: 26635177
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Differential cytotoxicity of novel somatostatin and dopamine chimeric compounds on bronchopulmonary and small intestinal neuroendocrine tumor cell lines.
    Kidd M; Drozdov I; Joseph R; Pfragner R; Culler M; Modlin I
    Cancer; 2008 Aug; 113(4):690-700. PubMed ID: 18618499
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Interaction between somatostatin analogues and targeted therapies in neuroendocrine tumor cells.
    Krug S; Mordhorst JP; Moser F; Theuerkorn K; Ruffert C; Egidi M; Rinke A; Gress TM; Michl P
    PLoS One; 2019; 14(6):e0218953. PubMed ID: 31237925
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The safety of lanreotide for neuroendocrine tumor.
    Godara A; Siddiqui NS; Byrne MM; Saif MW
    Expert Opin Drug Saf; 2019 Jan; 18(1):1-10. PubMed ID: 30582380
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Ki67 proliferation index, hepatic tumor load, and pretreatment tumor growth predict the antitumoral efficacy of lanreotide in patients with malignant digestive neuroendocrine tumors.
    Palazzo M; Lombard-Bohas C; Cadiot G; Matysiak-Budnik T; Rebours V; Vullierme MP; Couvelard A; Hentic O; Ruszniewski P
    Eur J Gastroenterol Hepatol; 2013 Feb; 25(2):232-8. PubMed ID: 23108416
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Lanreotide in metastatic enteropancreatic neuroendocrine tumors.
    Caplin ME; Pavel M; Ćwikła JB; Phan AT; Raderer M; Sedláčková E; Cadiot G; Wolin EM; Capdevila J; Wall L; Rindi G; Langley A; Martinez S; Blumberg J; Ruszniewski P;
    N Engl J Med; 2014 Jul; 371(3):224-33. PubMed ID: 25014687
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Safety review: dose optimization of somatostatin analogs in patients with acromegaly and neuroendocrine tumors.
    Ludlam WH; Anthony L
    Adv Ther; 2011 Oct; 28(10):825-41. PubMed ID: 21964965
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Antitumor effects of somatostatin analogs in neuroendocrine tumors.
    Sidéris L; Dubé P; Rinke A
    Oncologist; 2012; 17(6):747-55. PubMed ID: 22628056
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Neuroendocrine Tumors and Lanreotide Depot: Clinical Considerations and Nurse and Patient Preferences.
    Ryan P; Phan AT; Adelman DT; Iwasaki M
    Clin J Oncol Nurs; 2016 Dec; 20(6):E139-E146. PubMed ID: 27857269
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The expanding role of somatostatin analogs in gastroenteropancreatic and lung neuroendocrine tumors.
    Cives M; Strosberg J
    Drugs; 2015 May; 75(8):847-58. PubMed ID: 25911185
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prospective, randomized, multicenter trial on the antiproliferative effect of lanreotide, interferon alfa, and their combination for therapy of metastatic neuroendocrine gastroenteropancreatic tumors--the International Lanreotide and Interferon Alfa Study Group.
    Faiss S; Pape UF; Böhmig M; Dörffel Y; Mansmann U; Golder W; Riecken EO; Wiedenmann B;
    J Clin Oncol; 2003 Jul; 21(14):2689-96. PubMed ID: 12860945
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Lanreotide promotes apoptosis and is not radioprotective in GH3 cells.
    Ning S; Knox SJ; Harsh GR; Culler MD; Katznelson L
    Endocr Relat Cancer; 2009 Sep; 16(3):1045-55. PubMed ID: 19528243
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Ultra-high-dose lanreotide treatment in patients with metastatic neuroendocrine gastroenteropancreatic tumors.
    Faiss S; Räth U; Mansmann U; Caird D; Clemens N; Riecken EO; Wiedenmann B
    Digestion; 1999; 60(5):469-76. PubMed ID: 10473972
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The antitumoral effect of the long-acting somatostatin analog lanreotide in neuroendocrine tumors.
    Ducreux M; Ruszniewski P; Chayvialle JA; Blumberg J; Cloarec D; Michel H; Raymond JM; Dupas JL; Gouerou H; Jian R; Genestin E; Hammel P; Rougier P
    Am J Gastroenterol; 2000 Nov; 95(11):3276-81. PubMed ID: 11095353
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Update on the management of neuroendocrine tumors: focus on somatostatin antitumor effects.
    Gardner-Roehnelt NM
    Clin J Oncol Nurs; 2012 Feb; 16(1):56-64. PubMed ID: 22297008
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Lanreotide Depot: An Antineoplastic Treatment of Carcinoid or Neuroendocrine Tumors.
    Wolin EM; Manon A; Chassaing C; Lewis A; Bertocchi L; Richard J; Phan AT
    J Gastrointest Cancer; 2016 Dec; 47(4):366-374. PubMed ID: 27619395
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Evaluation of the efficacy and safety of lanreotide in combination with targeted therapies in patients with neuroendocrine tumours in clinical practice: a retrospective cross-sectional analysis.
    Capdevila J; Sevilla I; Alonso V; Antón Aparicio L; Jiménez Fonseca P; Grande E; Reina JJ; Manzano JL; Alonso Lájara JD; Barriuso J; Castellano D; Medina J; López C; Segura Á; Carrera S; Crespo G; Fuster J; Munarriz J; García Alfonso P
    BMC Cancer; 2015 Jul; 15():495. PubMed ID: 26138480
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effects of the somatostatin analog lanreotide on the circulating levels of chromogranin-A, prostate-specific antigen, and insulin-like growth factor-1 in advanced prostate cancer patients.
    Berruti A; Dogliotti L; Mosca A; Tarabuzzi R; Torta M; Mari M; Gorzegno G; Fontana D; Angeli A
    Prostate; 2001 May; 47(3):205-11. PubMed ID: 11351350
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Somatostatin analogues: treatment of pituitary and neuroendocrine tumors.
    Colao A; Faggiano A; Pivonello R
    Prog Brain Res; 2010; 182():281-94. PubMed ID: 20541670
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.